Free Trial
NASDAQ:CLSD

Clearside Biomedical (CLSD) Stock Price, News & Analysis

Clearside Biomedical logo
$0.82 -0.01 (-0.60%)
As of 01:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Clearside Biomedical Stock (NASDAQ:CLSD)

Key Stats

Today's Range
$0.82
$0.85
50-Day Range
$0.74
$0.90
52-Week Range
$0.70
$1.65
Volume
29,165 shs
Average Volume
216,154 shs
Market Capitalization
$64.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75
Consensus Rating
Buy

Company Overview

Clearside Biomedical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

CLSD MarketRank™: 

Clearside Biomedical scored higher than 40% of companies evaluated by MarketBeat, and ranked 700th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Clearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Clearside Biomedical has only been the subject of 3 research reports in the past 90 days.

  • Read more about Clearside Biomedical's stock forecast and price target.
  • Earnings Growth

    Earnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.48) to ($0.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Clearside Biomedical is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Clearside Biomedical is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Clearside Biomedical's valuation and earnings.
  • Percentage of Shares Shorted

    0.54% of the float of Clearside Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Clearside Biomedical has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Clearside Biomedical has recently increased by 13.75%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Clearside Biomedical does not currently pay a dividend.

  • Dividend Growth

    Clearside Biomedical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.54% of the float of Clearside Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Clearside Biomedical has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Clearside Biomedical has recently increased by 13.75%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Clearside Biomedical has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Clearside Biomedical this week, compared to 2 articles on an average week.
  • Search Interest

    5 people have searched for CLSD on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Clearside Biomedical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.20% of the stock of Clearside Biomedical is held by insiders.

  • Percentage Held by Institutions

    Only 18.75% of the stock of Clearside Biomedical is held by institutions.

  • Read more about Clearside Biomedical's insider trading history.
Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Stock News Headlines

The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
See More Headlines

CLSD Stock Analysis - Frequently Asked Questions

Clearside Biomedical's stock was trading at $0.95 at the start of the year. Since then, CLSD stock has decreased by 13.1% and is now trading at $0.8260.

Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. The business had revenue of $2.33 million for the quarter, compared to the consensus estimate of $0.20 million.

Clearside Biomedical (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), NVIDIA (NVDA), T2 Biosystems (TTOO), Advanced Micro Devices (AMD) and (ZLTQ) (ZLTQ).

Company Calendar

Last Earnings
5/14/2025
Today
7/15/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CLSD
CIK
1539029
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$3.00
Potential Upside/Downside
+473.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.35 million
Net Margins
-818.57%
Pretax Margin
-799.60%
Return on Equity
N/A
Return on Assets
-114.23%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.19
Quick Ratio
3.19

Sales & Book Value

Annual Sales
$1.66 million
Price / Sales
38.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.51) per share
Price / Book
-1.63

Miscellaneous

Outstanding Shares
77,710,000
Free Float
72,891,000
Market Cap
$64.42 million
Optionable
Optionable
Beta
2.05

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CLSD) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners